A total of 31 consecutive patients with hematologic malignancies who were considered poor candidates for TBI underwent allogeneic stem cell transplantation after conditioning with fludarabine and melphalan. A total of 25 matched sibling recipients received fludarabine 25 mg/ m 2 Â 5 days and melphalan 70 mg/m 2 Â 2 days. For unrelated and haploidentical donor recipients, fludarabine was increased to 30 mg/m 2 and ATG 30 mg/kg Â 4 days was added. Graft-versus-host disease prophylaxis consisted of tacrolimus and mini methotrexate. All patients engrafted. Regimen-related toxicity was considerable and included mainly renal, hepatic and mucosal toxicity. There were seven regimen-related-deaths including two VOD, two pulmonary, one renal, one cardiac and one mucosal toxicity. One case of fatal pulmonary toxicity death could be attributed to pre-existing pulmonary damage. Progression-free survival at 12 months was 44% (90% CI: 30-58%) for recipients of HLA-identical sibling transplants and 33% (90% CI: 21-45%) for all patients. In conclusion, the fludarabine-melphalan regimen leads to consistent engraftment. The regimen-related toxicity is considerable and cannot be explained solely by patient selection. Cardiac toxicity is emerging as a unique toxicity of this regimen. Despite toxicity, fludarabinemelphalan has considerable activity and leads to durable remission in a proportion of patients. Bone Marrow Transplantation (2003) 32, 471-476. doi:10.1038/sj.bmt.1704166 Keywords: fludarabine; melphalan; nonmyeloablative; transplantation Patients with advanced hematologic malignancies are considered incurable with conventional chemotherapy, but can occasionally be cured with allogeneic transplantation. The impact of allogeneic transplantation is unfortunately limited because of high recurrence rates and due to treatment-related complications in patients with considerable comorbidities. A number of new preparative regimens have been evaluated, which avoid the use of full-dose TBI.
transplantation
Patients with advanced hematologic malignancies are considered incurable with conventional chemotherapy, but can occasionally be cured with allogeneic transplantation. The impact of allogeneic transplantation is unfortunately limited because of high recurrence rates and due to treatment-related complications in patients with considerable comorbidities. A number of new preparative regimens have been evaluated, which avoid the use of full-dose TBI. [1] [2] [3] For patients considered ineligible for TBI, we studied the fludarabine-melphalan preparative regimen and report our experience in 31 consecutive patients. This regimen was developed specifically for patients with advanced hematologic malignancies. 1 We confirmed its ability to induce engraftment but observed considerable regimen-related toxicity associated with this regimen that could not be explained solely by patient selection.
Patients and methods

Patients and protocol
Patients were eligible if they had hematologic malignancies including acute and chronic leukemia and myeloproliferative disorders, non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma. Patients with acute leukemia in first remission were enrolled only if they had unfavorable cytogenetics.
Additional eligibility criteria included, Karnofsky performance status greater than or equal to 60%, bilirubin less than or equal to 2 mg/dl, creatinine less than 1.5 times normal.
Patients were enrolled on this protocol only if they were considered ineligible for TBI, because of prior radiation, prior transplant, 4 advanced age or a history of recent infections.
The protocol was approved by the institutional review board of the University of Illinois at Chicago. All patients and donors provided written informed consent.
Pretransplant work-up included CT scan of chest and sinuses, left ventricular ejection fraction, pulmonary function testing, renal and liver function tests as well as infectious disease serologies.
Preparative regimen
HLA-identical transplant recipients received fludarabine 25 mg/m 2 /day for five consecutive days (days À6, À5, À4, À3, À2) and melphalan 70 mg/m 2 /day on days À3 and À2. For recipients of two-antigen and three-antigen mismatched related transplantation and for recipients of matched unrelated donor transplantation, the dose of fludarabine was increased to 30 mg/m 2 /day. They also received antithymocyte globulin (ATGAM) 30 mg/kg/day i.v. on days À4, À3, À2 and -1.
Donor stem cell mobilization and stem cell processing
A total of 25 donors for HLA-identical siblings underwent stem cell mobilization using G-CSF 5 mg/kg b.i.d. for five consecutive days. Collection was started on day 5 and continued daily until 5 Â 10 6 CD 34 cells/kg were collected. Four donors for haploidentical relatives were mobilized with G-CSF 8 mg/kg subcutaneously every 12 h. Leukapheresis was started on the fourth day of G-CSF administration, and continued until a target CD34+ cell dose of 15-20 Â 10 6 CD34+ cells/kg recipient had been collected. These cells were T-cell depleted using the Baxter Isolex 300i system or the Miltenyi Clinimax system prior to cryopreservation. Two unrelated donors underwent one or two collections after G-CSF mobilization as per NMDP policy. These stem cells were infused without further manipulations.
Post transplant GVHD prophylaxis
All patients received graft-versus-host disease (GVHD) prophylaxis consisting of tacrolimus and minimethotrexate. Tacrolimus was given from day À2 until day 180. The dose was adjusted to achieve levels of 5-15 ng/ml. Thereafter, tacrolimus was tapered unless there was evidence of acute or chronic GVHD. Methotrexate 5 mg/m 2 was administered on days +1, +3 and +6 after transplantation. 5 
Supportive care and growth factors
A total of 27 patients received G-CSF 5 mg/kg/day subcutaneously starting on day 7 after transplantation until a neutrophil count of 41.5 Â 10 9 /l for three consecutive days had been reached. Four recipients of twoantigen or three-antigen mismatched related transplants received GM-CSF 250 mg/m 2 /day starting on day 7. 6 All patients received levofloxacin 500 mg/day p.o. until resolution of neutropenia and fluconazole 200 mg/day until day 180. Trimethoprim/sulfamethoxazole 2 doublestrength tablets daily twice a week were given from engraftment until 1 year after transplantation. Acyclovir 10 mg/kg q 8 h i.v. until discharge followed by 800 mg p.o. b.i.d. or t.i.d. was administered to all patients until day 180 except for those receiving ganciclovir (see below), or those who were both HSV negative and CMV-negative and had a CMV-negative donor.
Prophylactic ganciclovir was given as previously described to recipients of haploidentical T-cell-depleted transplantation. 7 All other patients were screened weekly for CMV-viremia and treated with ganciclovir upon detection of CMV-viremia. Antifungal, antiviral and PCP prophylaxis continued indefinitely for those with active GVHD or those on immunosuppressive treatment.
All patients were treated in high-efficiency, particulate-free air (HEPA-filter) rooms with strict reverse isolation. Irradiated and leucodepleted blood products were administered to maintain a hemoglobin level of greater than 8 g/dl and platelet count of greater than 20 Â 10 9 /l.
Post transplant evaluation
Patients were scored as treatment failures when overt progression of disease by clinical, radiological or pathological criteria was documented, or when they died from transplant-related causes.
Regimen-related toxicity was scored using the criteria of Bearman et al. 8 In this system, grade I toxicity is reversible without treatment and grade 2 is not life threatening, but requires treatment. Grade 3 requires life-support intervention and grade 4 is fatal. Regimen-related toxicity in each organ system was scored as the highest grade achieved in that organ system through day 28, except that deaths occurring after day 28 as a result of regimen-related toxicity occurring before day 28 were also scored as grade 4. Adverse events that could be attributed to infection (culture-documented), bleeding or other medications were not scored as regimen-related toxicity. The maximum toxicity was the highest grade recorded in any individual organ system and the cumulative toxicity score was the sum of the highest grades recorded for all eight organ systems.
Patients were evaluated for acute and chronic GVHD, and GVHD was scored and treated according to standard criteria. 9 
Engraftment analysis
Bone marrow and/or peripheral blood specimens were collected at approximately days 28, 100 and 180 following transplant. Donor and recipient cells were detected by quantitative analysis of informative microsatellite sequences of DNA using the genescan system. Genomic DNA amplification was performed using the AmpFlstr Profiler Kit which contains all reagents needed to amplify nine different informative STRs and the Amelogenin gene. 9 One primer of each locus-specific primer pair was labeled with either the 5-FAM, JOE or NED NHS-ester dye, which is detected as blue, green and yellow, respectively. A positive DNA control, 9947A, which is contained within the kit, was included in all assays. In addition, a negative control, amplification reaction without template, was amplified with all patient PCR amplifications. All patient templates, along with DNA extracted from cell lines (CEM, DHL-6 or DHL-16), were amplified using primers specific for the ABL gene to verify the quality of the DNA. In mixing studies, the sensitivity for detection of donor chimerism was 1%.
Statistical methods
A t-test was used for comparison of regimen-related toxicity between groups. Progression-free survival, overall survival, cumulative probability of chronic GVHD and extensive chronic GVHD were calculated using the Kaplan-Meier product-limit estimate and expressed as probabilities with a 95% confidence interval. 10 Univariate comparisons used the log-rank test. The long-term outcome analyses were performed for the entire patient group and Toxicity of fludarabine-melphalan K van Besien et al separately for recipients of HLA-identical sibling transplantation. All P-values are two-sided.
Results
Patients
From 1997 until July 2001, 31 consecutive patients were enrolled. Their characteristics are summarized in Table 1 .
Reasons for recommending fludarabine-melphalan rather than a TBI-containing regimen were: advanced age (3), prior autologous (9) or allogeneic transplantation (4), limited pulmonary function (3), a history of liver dysfunction with prior chemotherapy (2), HCV-seropositivity (1), recent pneumonia (3) or decrease in performance status due to underlying disease (4) . Median age at transplantation was 47 (range 12-63). All but two patients had advanced hematologic malignancies; 15 patients had advanced stages of AML or MDS; five patients had advanced CML or myelofibrosis; nine patients had advanced lymphoma, myeloma, CLL or ALL; 13 patients had undergone a prior autologous or allogeneic transplantation.
A total of 25 patients whose donor was an HLA-identical sibling and two recipients of unrelated donor transplant (one completely matched in 10 loci tested by highresolution typing and one with an allele mismatch in HLA-A and antigen mismatch in HLA-C) received unmanipulated peripheral blood progenitor cells. Four recipients of two-antigen or three-antigen mismatched related transplants received T-cell-depleted PBPC.
Engraftment
Trilineage engraftment occurred in all evaluable patients. Chimerism studies demonstrated 100% donor chimerism in blood and bone marrow in all evaluable patients by day 28.
Regimen-related toxicity and treatment-related mortality
Regimen-related toxicity is summarized in Table 2 . Mucositis, renal and pulmonary toxicity were most common. There were however also two cases of fatal hepatic toxicity and one case of fatal cardiac toxicity. There was no significant difference in cumulative or maximal regimenrelated toxicity between those over age 40 years vs those under the age of 40 years, recipients of HLA-identical sibling transplants vs recipients of unrelated or haploidentical transplants, those with AML vs those with other diagnoses and those who had undergone a previous transplant vs those who did not.
There were seven regimen-related deaths. The characteristics of these patients are summarized in Table 3 . Two patients died from respiratory failure and ARDS. One was a 21-year-old male with a history of testicular cancer and secondary MDS. He had reduced pulmonary function tests prior to transplant, probably due to prior exposure to bleomycin. He developed ARDS by day 0 and died by day 30 after transplant. The other one was a 46-year-old woman undergoing a matched unrelated donor transplant for refractory mantle cell lymphoma, after failing a previous autologous transplant. She died by day 19 after transplant. Her pulmonary function tests were normal prior to transplant. A 63-year-old woman with refractory AML and a 50-year-old woman with refractory mantle cell lymphoma, who had failed a prior autologous transplant, died of hepatic veno-occlusive disease. They had normal pretransplant liver function tests. A 57-year-old man with AML in first remission died by day 10 after transplant from congestive heart failure. Except for hypertension, he had no history of cardiovascular disease and his cardiac ejection fraction prior to admission was 70%. A 44-year-old woman with relapsed AML developed severe mucositis, which required intubation and ultimately led to her death. She had been offered the fludarabine-melphalan regimen because of a history of recently resolved pneumonia. Renal function and liver function tests prior to transplantation had been normal. Finally, a 48-year-old woman who had failed a prior autologous transplant developed acute renal failure within several days from stem cell infusion from her haploidentical daughter. Renal function prior to transplantation had been normal.
In addition, there were two cases of fatal delayed pulmonary toxicity. A 63-year-old man with a history of acute GVHD developed treatment refractory bronchiolitis obliterans and died 17 months after transplant from LGL=low-grade lymphoma; MCL=mantle cell lymphoma; NHL=non-Hodgkin's lymphoma; HD=Hodgkin's disease.
Table 2
Regimen-related toxicity; bearman scores 
GVHD
Only one case of grade III acute GVHD was observed among 25 HLA-identical sibling donor transplants. None were observed among the recipients of T-cell-depleted haploidentical transplantation. The recipients of mismatched unrelated donor transplantation died of severe acute GVHD. Eight patients are currently alive. Seven have developed chronic GVHD, and six continue to require treatment.
Progression-free survival, survival, relapse
Kaplan-Meier event-free survival at 12 months was 44% (90% CI: 30-58%) for recipients of HLA-identical sibling transplants and 33% (90% CI: 21-45%) for all patients (Figure 1 ). Cumulative rate of disease recurrence was 33% (90% CI: 21-45%).
Discussion
Allogeneic transplantation has yielded the best responses in young patients with acute leukemia in first remission and CML in chronic phase. [11] [12] [13] The large majority of patients with hematologic malignancy are however over the age of 60 years, have malignancies with adverse prognostic features and considerable comorbidities. Increasingly, transplantation is offered for such patients, but it is curative for only a small minority of them.
14 Treatmentrelated mortality and disease recurrence constitute closely inter-related causes of treatment failure. The use of donor stem cells rather than donor bone marrow has somewhat improved outcome of patients with advanced leukemia but recurrence rates and treatment complications remain considerable. 15, 16 A large proportion of patients with advanced hematologic malignancies have received prior dose-limiting radiation. Such patients, as well as the elderly, were offered a conditioning regimen based on the antitumoral activity of melphalan 17 and the immunosuppressive activities of both melphalan 18 and fludarabine. 19 This regimen was developed by the MD Anderson group who reported consistent engraftment and durable remissions in some patients with advanced hematologic malignancies.
1 They reported grade 3-4 regimen-related toxicity in 10 of 78 patients and attributed three of 29 treatment-related deaths to regimen-related toxicity. All other deaths were attributed to GVHD and infection. We confirmed the findings of Giralt et al that the fludarabinemelphalan regimen leads to consistent engraftment in recipients of HLA-identical stem cell transplantation. 1 In combination with ATG, it also leads to engraftment in recipients of matched unrelated donor grafts and in recipients of T-cell-depleted haploidentical transplantation.
In contrast to the report by the MD Anderson group, we encountered significant mucosal, pulmonary, renal, hepatic and cardiac toxicity after fludarabine-melphalan. Except for a slightly decreased incidence of mucositis, the average regimen-related toxicities were not different from that observed in a parallel cohort of patients receiving TBI. 20 Seven out of 30 patients (23%) died of regimen-related toxicity. While it is tempting to attribute toxicity to patient selection, pre-existing damage in the target organ was present only in one case of pulmonary toxicity. The six other cases of fatal toxicity include one additional pulmonary toxicity, one renal, one mucosal, one cardiac Table 3 Characteristics of seven patients with fatal regimen-related toxicity Toxicity of fludarabine-melphalan K van Besien et al and two cases of hepatic toxicity. In none of these cases was there evidence of pre-existing organ damage or exposure to excessive doses of particularly noxious agents. Hence, a considerable percentage of the toxicity encountered with fludarabine melphalan has to be attributed directly to the treatment regimen. This is not surprising, given the welldocumented medullary and extramedullary toxicities of high-dose melphalan. 17, 21 Intravenous melphalan at doses of 140 mg/m 2 without stem cell support results in a median duration of neutropenia of 23-30 days. It is likely that fludarabine adds to the myelosuppression caused by highdose melphalan. Extramedullary toxicities of high-dose melphalan include mucositis, pulmonary, renal and hepatic toxicity. 17, 21 The latter toxicities are likely to be much exacerbated by the use of methotrexate and tacrolimus post-transplantation. Methotrexate in particular can cause severe mucositis and contributes to hepatic toxicity; tacrolimus contributes to hepatic and renal toxicity, and like cyclosporine may interact with the metabolism of melphalan. [22] [23] [24] Cardiac toxicity has only rarely been reported with high-dose melphalan or with fludarabine used as single agents. Recently, Ritchie et al 25 reported three cases of severe cardiac toxicity among patients receiving fludarabine-melphalan conditioning. As in the case of our patients, none of their patients had a history of cardiac disease and all of them had normal pretransplant cardiac function. Of interest, in the MD Anderson series, there were two cases of grade 3-4 cardiac toxicity as well 1 and in a series from Spain, one of 48 patients died of early cardiac toxicity. 26 The mechanism of this unique toxicity is not known. 25 Our observations are not necessarily in conflict with those from the MD Anderson group. The overall treatment-related mortality is in the same range. Regimen-related toxicity, acute GVHD and opportunistic infections are closely related and occur in parallel in many cases. 27 The apparent discrepancy in causes of death between our study and the one from the MD Anderson Cancer Center is likely related to differences in interpretation of what constitutes the primary cause of death in an individual patient.
Among patients surviving beyond 100 days after blood stem cell transplantation, disease recurrence and especially extensive chronic GVHD constitute major problems. 28 Chronic GVHD likely contributed to the occurrence of delayed pulmonary toxicity in two patients. 29 Despite these limitations, the fludarabine-melphalan regimen is of considerable interest. It is convenient to administer, assures consistent engraftment and appears to be curative in a subgroup of patients. In our experience, the rates of durable remission were equivalent to those obtained with a TBI regimen. 20 When combined with less toxic forms of GVHD prophylaxis (such as replacing methotrexate with Campath), the fludarabine-melphalan regimen appears better tolerated and may serve as a platform for testing specific immunotherapy approaches. 30 A large number of 'nonmyeloablative' preparative regimens have been tested recently. While it has been convincingly demonstrated that engraftment can be reliably obtained with such regimens, the reported incidences of treatment-related morbidity and mortality vary widely. [1] [2] [3] 31, 32 Stem cell source, GVHD prophylaxis regimen and patient selection are all important variables affecting observed side effects. Only large prospective studies will be able to elucidate the specific toxicities of each of these regimens. In the meantime, the use of terms such as 'minitransplant' or 'transplant-lite' is misleading and should be avoided. 33 
